Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
Weight Loss StackEvidence Grade: A (Semaglutide) / B (AOD-9604)
Semaglutide + AOD-9604 Stack Protocol Guide
The Semaglutide + AOD-9604 stack combines the most powerful GLP-1 receptor agonist with a targeted fat-loss peptide for enhanced body composition results. Semaglutide suppresses appetite via central GLP-1 signaling, slows gastric emptying, and improves insulin sensitivity, while AOD-9604 (a modified fragment of human growth hormone amino acids 177-191) directly stimulates lipolysis without growth-promoting or diabetogenic effects. Together, these compounds address fat loss through complementary mechanisms: reduced caloric intake via appetite suppression and direct fat mobilization from adipose tissue.
Semaglutide activates GLP-1 receptors in the hypothalamus and gut, producing powerful appetite suppression, delayed gastric emptying, and improved insulin sensitivity. In clinical trials (STEP program), semaglutide produced 15-20% body weight reduction. It addresses the behavioral component of fat loss by dramatically reducing hunger and cravings.
AOD-9604 Synergy
AOD-9604 is the lipolytic fragment of HGH (amino acids 177-191) that directly stimulates fat breakdown in adipose tissue without affecting blood sugar or growth. While semaglutide reduces caloric intake from the top down, AOD-9604 attacks stored fat from the bottom up, specifically mobilizing stubborn adipose deposits that resist diet alone.
